Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 606 (LINC00606) is a human long non-coding RNA (lncRNA), specifically a long intergenic non-coding RNA (lincRNA) that does not overlap protein-coding genes. LINC00606 is highly expressed in some tumor types, notably glioblastoma, where it drives cell proliferation and migration, and suppresses apoptosis. Functionally, it regulates gene networks through sponging microRNAs (e.g., miR-486-3p), modulating the expression of genes like TCF12, and interacting with the protein ATP11B to impact signaling pathways including PI3K/AKT. Its high expression is associated with poor prognosis in glioma, suggesting its utility as a biomarker. No approved drugs directly target LINC00606, and therapeutic targeting is an emerging research area rather than established clinical reality.
Acts as a competing endogenous RNA ("molecular sponge") for microRNAs such as miR-486-3p, thereby regulating the expression of downstream genes (e.g., TCF12); Binds to proteins (e.g., ATP11B) and modulates the PI3K/AKT signaling pathway
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 606 (LINC00606).